Liquid Biopsy Market, Analysis and Forecast, 2017-2025 - SITE LICENSE

A biopsy is the most common, definitive medical procedure used for cancer diagnosis and treatment monitoring. Tissue biopsy, is widely adopted procedure to diagnose cancer. However, a major drawback for tissue based diagnosis approach is its dependency on invasive surgical procedures which in many instances preclude the regular treatment monitoring and sometimes the initial diagnosis too. The search for better minimal invasive diagnostic procedures to aid regular monitoring of the patient’s response towards the treatment gave birth to liquid biopsy tests. In the recent years, the impressive research on cancer biomarkers’ presence in biological fluids, such as blood, which can be collected through minimal invasive techniques has yielded promising results to develop better minimal invasive diagnostics procedures known as liquid biopsies.

Liquid biopsy is a minimal invasive medical procedure with the ability to detect the presence of molecular cancer biomarkers in the biological fluids. The derived test results help the doctors in deciding the further steps in the treatment of the patient suffering from cancer. The test principally involves the usage of samples of biological fluids, such as blood, urine, serum, and saliva, among others, and then the enrichment of the samples using different techniques, such as Next generation Sequencing (NGS), and Polymerase Chain Reaction (PCR), to detect the mutations known to cause cancer.
The liquid biopsy market is expected to grow at a near double digit annual growth rate. The abilities of liquid biopsy, such as minimal invasiveness, possibility of continuous monitoring of the patient’s response towards treatment, and the monitoring of clonal mutations, combined with the growing prominence for precision medicine have fueled the growth of the liquid biopsy market.
The research study comprises in-depth analysis of the market trends and market size through different approaches. The entire market has been segmented and estimated in five different approaches, namely “by product & services”, “by biomarker and technology”, “by cancer type”, “by end users”, and “by geography”.
In terms of “by products & services”, the market has been segmented into kits & reagents, platforms & instruments, and services. In terms of “by biomarker and technology” the market has been segmented into circulating tumor cell (CTC), circulating tumor DNA (ctDNA), and extracellular vesicles (EV). In terms of “by cancer type” the market has been segmented into lung cancer, breast cancer, colorectal cancer, prostate cancer, and liver cancer. In terms of “by end users” the market has been tracked through hospital & laboratory, government & academic research centers. And in terms of “by geography” the market has been segmented into North America, Europe, Asia Pacific, and LAMEA.
Some of the key players who have been contributing significantly to the liquid biopsy market are Janssen Diagnostics, LLC, Biocept Inc., Bio-Rad Laboratories Inc., Guardant Health, Inc., Myriad Genetics, QIAGEN, RainDance Technologies, Roche AG, Trovagene Inc., Adaptive Biotechnologies, Natera, Inc., Cynvenio Biosystems, Inc., Epic Sciences, ANGLE plc, Illumina, Inc., Menarini Silicon Biosystems., MDxHealth, Sysmex Inostics GmbH, Genomic Health, and NeoGenomics Laboratories, Inc.
The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into the consideration before entering into the global liquid biopsy market.
The answers to the following key questions can be derived from this report:
• What are the major market drivers, challenges, and opportunities in the global liquid biopsy market?
• How did the liquid biopsy market evolve and what is its scope in the future?
• What are the key developmental strategies which are being implemented by the key players to stand out in this market?
• What is the total addressable market (TAM), segmental addressable market (SAM) and the potential market opportunity of the global liquid biopsy market?
• What is the market share of the leading segments and sub-segments of the liquid biopsy market in 2016 and 2025?
• How will each segment of the global liquid biopsy market grow during the forecast period and what will be their revenue generation at the end of 2025?
• Who are the key players dominating the global liquid biopsy market and their respective share?
• What are the influencing factors that may affect the market share of the key players?
• How will the industry evolve during the forecast period 2016-2025?
• Which product type is dominating the market?
• What are the dominating products offered by different companies for each product type, available in the market?
• How the market is distributed on the basis of application?
• Which cancer type is the leading contributor to the global liquid biopsy market revenue?
• Which geographical location will contribute to the highest sales of the liquid biopsy products?
This research report aims at answering various aspects of the global liquid biopsy market with the help of key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The study considers the growth-share matrix model for a comprehensive study of the global liquid biopsy market and assesses the factors governing the same.
Executive Summary
1 Report Scope & Methodology
1.1 Scope of the Report
1.2 Market segmentation
1.3 Research Methodology
1.3.1 Data Triangulation
1.3.2 Key Data Points From Primary Sources
1.3.3 Key Data Points From Secondary Sources
1.3.4 Secondary Data Sources
1.3.5 Top-Down Approach (Segmental Analysis)
1.3.6 Bottom-Up Approach (Segmental Analysis)
1.4 Assumptions and Limitations
1.5 Data and Prediction Modelling
2 Market Overview
2.1 Introduction
2.2 Overview of Liquid Biopsy Techniques and Applications
2.3 Historical trends
2.4 Comparative Analysis of Tissue Biopsy and Liquid Biopsy
3 Market Dynamics
3.1 Promoting and Inhibiting Factors of Liquid Biopsy Market Growth
3.2 Drivers
3.3 Restraints
3.4 Opportunities
4 Competitive Insights
4.1 Share of Key Development and Strategies
4.2 Competitive Landscape
4.3 Market Share Analysis
4.4 Industry Attractiveness
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 Global Liquid Biopsy Market, by Product
5.1 Overview
5.2 Kits and Consumables
5.3 Instruments
5.4 Services
6 Global Liquid Biopsy Market, by Type of Biomarker
6.1 Overview
6.2 Circulating Tumor Cell (CTC)
6.3 Circulating Tumor DNA (ctDNA)
6.4 Extracellular Vesicles (EVs)
6.5 Other Types of Biomarkers
7 Global Liquid Biopsy Market, by Cancer Type
7.1 Liquid Biopsy's Role in Cancer Detection: An Overview
7.2 Liquid Biopsy: Role in Lung Cancer Diagnosis
7.3 Liquid Biopsy: Role in Breast Cancer Diagnosis
7.4 Liquid Biopsy: Role in Colorectal Cancer Diagnosis
7.5 Liquid Biopsy: Role in Prostate Cancer Diagnosis
7.6 Liquid Biopsy: Role in Liver Cancer Diagnosis
7.7 Liquid Biopsy: Role in Other Cancer Diagnosis
8 Global Liquid Biopsy Market, by End User
8.1 Overview
8.2 Reference Laboratories
8.3 Hospitals and Physician Laboratories
8.4 Academic and Research Centers
8.5 Other End Users
9 Global Liquid Biopsy Market, by Geography
9.1 Overview
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 U.K.
9.3.2 Germany
9.3.3 France
9.3.4 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Rest of the Asia Pacific
9.5 Rest of the World
10 Company Profile
10.1 Adaptive Biotechnologies
10.1.1 Overview
10.1.2 Adaptive Biotechnologies: Corporate Summary
10.1.3 Adaptive Biotechnologies: SWOT Analysis
10.2 ANGLE plc
10.2.1 Overview
10.2.2 Financials
10.2.2.1 Financial Summary
10.2.3 ANGLE plc: SWOT Analysis
10.3 Biocept, Inc.
10.3.1 Overview
10.3.2 Financials
10.3.2.1 Financial Summary
10.3.3 Biocept, Inc.: SWOT Analysis
10.4 Bio-Rad Laboratories, Inc.
10.4.1 Overview
10.4.2 Bio-Rad Laboratories, Inc.: Product Portfolio
10.4.3 Financials
10.4.3.1 Financial Summary
10.4.4 Bio-Rad Laboratories, Inc.: SWOT Analysis
10.5 CareDx, Inc.
10.5.1 Overview
10.5.2 Financials
10.5.2.1 Financial Summary
10.5.3 CareDx, Inc.: SWOT Analysis
10.6 Cynvenio Biosystems, Inc.
10.6.1 Overview
10.6.2 Cynvenio Biosystems, Inc.: Product Portfolio
10.6.3 Corporate Summary
10.6.4 Cynvenio Biosystems, Inc.: SWOT Analysis
10.7 Epic Sciences, Inc.
10.7.1 Overview
10.7.2 Epic Sciences, Inc.: Corporate Summary
10.7.3 Epic Sciences, Inc.: SWOT Analysis
10.8 F. Hoffmann-La Roche AG
10.8.1 Overview
10.8.2 F. Hoffmann-La Roche AG: Product Portfolio
10.8.3 Financials
10.8.3.1 Financial Summary
10.8.4 F. Hoffmann-La Roche AG: SWOT Analysis
10.9 Genomic Health, Inc.
10.9.1 Overview
10.9.2 Genomic Health, Inc.: Product Portfolio
10.9.3 Financials
10.9.3.1 Financial Summary
10.9.4 Genomic Health, Inc.: SWOT Analysis
10.10 GUARDANT HEALTH, INC
10.10.1 Overview
10.10.2 GUARDANT HEALTH, INC: Corporate Summary
10.10.3 GUARDANT HEALTH, INC: SWOT Analysis
10.11 Illumina, Inc.
10.11.1 Overview
10.11.2 Illumina, Inc.: Product Portfolio
10.11.3 Financials
10.11.3.1 Financial Summary
10.11.4 Illumina, Inc.: SWOT Analysis
10.12 JOHNSON & JOHNSON
10.12.1 Overview
10.12.2 JOHNSON & JOHNSON: Product Portfolio
10.12.3 Financials
10.12.3.1 Financial Summary
10.12.4 JOHNSON & JOHNSON: SWOT Analysis
10.13 MDxHealth, Inc.
10.13.1 Overview
10.13.2 Financials
10.13.2.1 Financial Summary
10.13.3 MDxHealth, Inc.: SWOT Analysis
10.14 Menarini Silicon Biosystems, Inc.
10.14.1 Overview
10.14.2 Menarini Silicon Biosystems, Inc.: Product Portfolio
10.14.3 Corporate Summary
10.14.4 Menarini Silicon Biosystems, Inc.: SWOT Analysis
10.15 Myriad Genetics, Inc.
10.15.1 Overview
10.15.2 Myriad Genetics, Inc.: Product Portfolio
10.15.3 Financials
10.15.3.1 Financial Summary
10.15.4 Myriad Genetics, Inc.: SWOT Analysis
10.16 Natera, Inc.
10.16.1 Overview
10.16.2 Natera, Inc.: Product Portfolio
10.16.3 Financials
10.16.3.1 Financial Summary
10.16.4 Natera, Inc.: SWOT Analysis
10.17 NeoGenomics Laboratories, Inc.
10.17.1 Overview
10.17.2 NeoGenomics Laboratories, Inc.: Product Portfolio
10.17.3 Financials
10.17.3.1 Financial Summary
10.17.4 NeoGenomics Laboratories, Inc.: SWOT Analysis
10.18 QIAGEN
10.18.1 Overview
10.18.2 QIAGEN: Product Portfolio
10.18.3 Financials
10.18.3.1 Financial Summary
10.18.4 QIAGEN: SWOT Analysis
10.19 RainDance Technologies, Inc.
10.19.1 Overview
10.19.2 RainDance Technologies, Inc.: Product Portfolio
10.19.3 Financials
10.19.3.1 Financial Summary
10.19.4 RainDance Technologies, Inc.: SWOT Analysis
10.20 Sysmex Corporation
10.20.1 Overview
10.20.2 Sysmex Corporation: Product Portfolio
10.20.3 Financials
10.20.3.1 Financial Summary
10.20.4 Sysmex Corporation: SWOT Analysis
10.21 Thermo Fisher Scientific
10.21.1 Overview
10.21.2 Thermo Fisher Scientific: Product Portfolio
10.21.3 Financials
10.21.3.1 Financial Summary
10.21.4 Thermo Fisher Scientific: SWOT Analysis
10.22 TROVAGENE, INC.
10.22.1 Overview
10.22.2 TROVAGENE, INC.: Product Portfolio
10.22.3 Financials
10.22.3.1 Financial Summary
10.22.4 TROVAGENE, INC.: SWOT Analysis
List of Tables
1 Cancer Incidence by Region, 2012 (Thousands)
2 Tissue Biopsy vs. Liquid Biopsy
3 Joint Ventures, Partnerships, Agreements and Collaborations
4 Product Launch
5 Mergers and Acquisitions
6 Regulatory Approval
7 Expansions and Others
8 List of Available Kits in the Market
9 List of Available Instruments and Platforms in the Market
10 List of Tests Available in the Market
11 Lung Cancer Incidence in Top Countries (2014-2025)
12 Breast Cancer Incidence in Top Countries (2014-2025)
13 Colorectal Cancer Incidence in Top Countries (2014-2025)
14 Prostate Cancer Incidence in Top Countries (2014-2025)
15 Liver Cancer Incidence in Top Countries (2014-2025)
16 Incidence Rate of Different Cancer Types, U.S. (2014-2025)
17 Incidence Rate of Different Cancer Types, Canada (2014-2025)
18 Incidence Rate of Different Cancer Types, U.K. (2014-2025)
19 Incidence Rate of Different Cancer Types, Germany (2014-2025)
20 Incidence Rate of Different Cancer Types, France (2014-2025)
21 Incidence Rate of Different Cancer Types, Italy (2014-2025)
22 Incidence Rate of Different Cancer Types, China (2014-2025)
23 Incidence Rate of Different Cancer Types, Japan (2014-2025)
24 Incidence Rate of Different Cancer Types, India (2014-2025)
25 Incidence Rate of Different Cancer Types, Australia (2014-2025)
26 Incidence Rate of Different Cancer Types, South Korea (2014-2025)
27 Incidence Rate of Different Cancer Types, Mexico (2014-2025)
28 Incidence Rate of Different Cancer Types, Turkey (2014-2025)
29 Incidence Rate of Different Cancer Types, Saudi Arabia (2014-2025)
30 Adaptive Biotechnologies: Overview
31 ANGLE plc: Overview
32 Biocept, Inc.: Overview
33 Bio-Rad Laboratories, Inc.: Overview
34 CareDx, Inc.: Overview
35 Cynvenio Biosystems, Inc.: Overview
36 Epic Sciences, Inc.: Overview
37 F. Hoffmann-La Roche AG: Overview
38 Genomic Health, Inc.: Overview
39 GUARDANT HEALTH, INC: Overview
40 Illumina, Inc.: Overview
41 JOHNSON & JOHNSON: Overview
42 MDxHealth, Inc.: Overview
43 Menarini Silicon Biosystems, Inc.: Overview
44 Myriad Genetics, Inc.: Overview
45 Natera, Inc.: Overview
46 NeoGenomics Laboratories, Inc.: Overview
47 QIAGEN: Overview
48 RainDance Technologies, Inc.: Overview
49 Sysmex Corporation: Overview
50 Thermo Fisher Scientific: Overview
51 TROVAGENE, INC.: Overview
List of Figures
1 Global Liquid Biopsy Market Revenue (2016-2025)
2 Global Liquid Biopsy Market Share, by Products and Services (2016)
3 Global Liquid Biopsy Market Share, by Products and Services (2025)
4 Global Liquid Biopsy Market Share, by Type of Biomarker (2016)
5 Global Liquid Biopsy Market Share, by Type of Biomarker (2025)
6 Global Liquid Biopsy Market Share, by Application (2016)
7 Global Liquid Biopsy Market Share, by Application (2025)
8 Global Liquid Biopsy Market Share, by End-User (2016)
9 Global Liquid Biopsy Market Share, by End-User (2025)
10 Liquid Biopsy Market Size, by Region
11 Liquid Biopsy Market Segmentation
12 Research Methodology
13 Evolution of Liquid Biopsy with Progress in Molecular Technologies and Biomarker Discovery
14 Comparative Analysis of Tissue Biopsy and Liquid Biopsy
15 Share of Key Development and Strategies
16 Market Share Analysis, by Companies (2015)
17 Market Share Analysis, by Companies (2016)
18 Porter’s Five Forces Analysis
19 Product Type Segmentation
20 Global Liquid Biopsy Market, by Product, 2016-2025 ($Million)
21 Global Liquid Biopsy Market Share, by Product, 2016-2025
22 Global Liquid Biopsy Kits & Consumables Market, 2016-2025
23 Global Liquid Biopsy Instruments Market, 2016-2025 ($Million)
24 Global Liquid Biopsy Services Market, 2016-2025 ($Million)
25 Different Biomarkers
26 Global Liquid Biopsy Market, by Biomarker Type, 2016-2025 ($Million)
27 Global liquid Biopsy Market, by Circulating Tumor Cells (CTCs), 2016-2025 ($Million)
28 List of Few CTC Based Kits and Instrument
29 Global liquid Biopsy Market, by Circulating Tumor DNA (ctDNA), 2016-2025 ($Million)
30 List of Few ctDNA Based Kits and Instrument
31 CTCs Vs ctDNA Analysis
32 Global liquid Biopsy Market, by Extracellular Vesicles (EVs), 2016-2025 ($Million)
33 Global liquid Biopsy Market, by Other Biomarkers (Cell Free DNA, etc.), 2016-2025 ($Million)
34 Standard Biopsy Vs Liquid Biopsy
35 Types of Lung Cancer
36 Lung Cancer Incidence Rate Statistics
37 List of Few Kits and Instruments for Lung Cancer Diagnosis
38 Types of Breast cancer
39 Breast Cancer Incidence Statistics
40 List of Few Kits and Instruments for Breast Cancer Diagnosis
41 Infected Colon and Rectum
42 List of Few Kits and Instruments for Colorectal Cancer Diagnosis
43 Colorectal Cancer Incidence Statistics
44 Prostate Cancer Incidence Statistics
45 List of Few Kits and Instruments for Prostate Cancer Diagnosis
46 Types of Liver Cancer
47 Liver Cancer Incidence Statistics
48 Global Liquid Biopsy Market Share, by End Users, 2016-2025
49 Global Liquid Biopsy Market, by End Users, 2016-2025 ($Million)
50 Global Liquid Biopsy End User Market, Reference Laboratories, 2016-2025 ($Million)
51 Global Liquid Biopsy End User Market, Hospitals and Physician Laboratories, 2016-2025 ($Million)
52 Global Liquid Biopsy End User Market, Academic and Research Centers, 2016-2025 ($Million)
53 Global Liquid Biopsy End User Market, Others, 2016-2025 ($Million)
54 Global Liquid Biopsy Market, by Region
55 Global Liquid Biopsy Market Revenue, by Region (2016-2025)
56 Global Liquid Biopsy Market Share, by Region (2016)
57 Global Liquid Biopsy Market Share, by Region (2025)
58 North America Liquid Biopsy Market Revenue (2016-2025)
59 North America Liquid Biopsy Market, by Products & Services (2016-2025)
60 North America Liquid Biopsy Market, by Country (2016-2025)
61 U.S. Liquid Biopsy Market Revenue (2016-2025)
62 Canada Liquid Biopsy Market Revenue (2016-2025)
63 Europe Liquid Biopsy Market Revenue (2016-2025)
64 Europe Liquid Biopsy Market, by Products & Services (2016-2025)
65 Europe Liquid Biopsy Market, by Country (2016-2025)
66 U.K. Liquid Biopsy Market Revenue (2016-2025)
67 Germany Liquid Biopsy Market Revenue (2016-2025)
68 France Liquid Biopsy Market Revenue (2016-2025)
69 Rest of Europe Liquid Biopsy Market Revenue (2016-2025)
70 Asia Pacific Liquid Biopsy Market Revenue (2016-2025)
71 Asia Pacific Liquid Biopsy Market, by Products & Services (2016-2025)
72 Asia Pacific Liquid Biopsy Market, by Country (2016-2025)
73 China Liquid Biopsy Market Revenue (2016-2025)
74 Japan Liquid Biopsy Market Revenue (2016-2025)
75 India Liquid Biopsy Market Revenue (2016-2025)
76 Rest of Asia Pacific Liquid Biopsy Market Revenue (2016-2025)
77 Rest of the World (RoW) Liquid Biopsy Market Revenue (2016-2025)
78 Adaptive Biotechnologies: SWOT Analysis
79 ANGLE plc: Overall Financials (2014-2016)
80 ANGLE plc: Revenue by Region
81 ANGLE plc: SWOT Analysis
82 Biocept, Inc.: Overall Financials (2014-2016)
83 Biocept, Inc.: SWOT Analysis
84 Bio-Rad Laboratories, Inc.: Product Mapping
85 Bio-Rad Laboratories, Inc.: Overall Financials (2014-2016)
86 Bio-Rad Laboratories, Inc.: Net Revenue by Business Segment (2014-2016)
87 Bio-Rad Laboratories, Inc.: Revenue by Region (2014-2016)
88 Bio-Rad Laboratories, Inc.: SWOT Analysis
89 CareDx: Overall Financials (2014-2016)
90 CareDx, Inc.: SWOT Analysis
91 Cynvenio Biosystems, Inc.: Product Mapping
92 Cynvenio Biosystems, Inc.: SWOT Analysis
93 Epic Sciences, Inc.: SWOT Analysis
94 F. Hoffmann-La Roche AG: Product Mapping
95 F. Hoffmann-La Roche AG: Overall Financials (2014-2016)
96 F. Hoffmann-La Roche AG: Revenue By Geographical Area (2014-2016)
97 F. Hoffmann-La Roche AG: Revenue by Division (2014-2016)
98 F. Hoffmann-La Roche AG: Revenue By Diagnostics Sub-Division (2014-2016)
99 F. Hoffmann-La Roche AG: SWOT Analysis
100 Genomic Health, Inc.: Product Mapping
101 Genomic Health, Inc.: Overall Financials (2014-2016)
102 Genomic Health, Inc.: Net Revenue by Region (2014-2016)
103 Genomic Health, Inc.: SWOT Analysis
104 GUARDANT HEALTH, INC: SWOT Analysis
105 Illumina, Inc: Product Mapping
106 Illumina, Inc.: Overall Financials (2014-2016)
107 Illumina, Inc.: Net Revenue by Business Segment (2014-2016)
108 Illumina, Inc.: Revenue by Region (2014-2016)
109 Illumina, Inc.: SWOT Analysis
110 JOHNSON & JOHNSON: Product Mapping
111 JOHNSON & JOHNSON: Overall Financials (2014-2016)
112 JOHNSON & JOHNSON: Net Revenue by Business Segment (2014-2016)
113 JOHNSON & JOHNSON: Net Revenue by Region (2014-2016)
114 JOHNSON & JOHNSON: Net Revenue by Medical Devices Business Segment (2014-2016)
115 JOHNSON & JOHNSON: SWOT Analysis
116 MDxHealth, Inc.: Overall Financials (2014-2016)
117 MDxHealth, Inc.: SWOT Analysis
118 Menarini Silicon Biosystems, Inc.: Product Mapping
119 Menarini Silicon Biosystems, Inc.: SWOT Analysis
120 Myriad Genetics, Inc.: Product Mapping
121 Myriad Genetics, Inc.: Overall Financials (2014-2016)
122 Myriad Genetics, Inc.: Net Revenue by Business Segment (2014-2016)
123 Myriad Genetics, Inc.: SWOT Analysis
124 Natera, Inc.: Product Mapping
125 Natera, Inc.: Overall Financials (2014-2016)
126 Natera, Inc.: Net Revenue by Region (2014-2016)
127 Natera, Inc.: SWOT Analysis
128 NeoGenomics Laboratories, Inc.: Product Mapping
129 NeoGenomics Laboratories, Inc.: Overall Financials (2014-2016)
130 NeoGenomics Laboratories, Inc.: Net Revenue by Business Segment (2014-2016)
131 NeoGenomics Laboratories, Inc.: SWOT Analysis
132 QIAGEN: Product Mapping
133 QIAGEN: Overall Financials (2014-2016)
134 QIAGEN: Net Revenue by Region (2014-2016)
135 Qiagen: Revenue by Business Segments (2014-2016)
136 QIAGEN: SWOT Analysis
137 RainDance Technologies, Inc.: Product Mapping
138 RainDance Technologies, Inc.: Overall Financials (2014)
139 RainDance Technologies: Net Revenue by Region (2014)
140 RainDance Technologies, Inc.: SWOT Analysis
141 Sysmex Corporation: Product Mapping
142 Sysmex Corporation: Overall Financials (2014- 2016)
143 Sysmex Corporation: Revenue by Business Segment (2014-2016)
144 Sysmex Corporation: Revenue by Region(2014-2016)
145 Sysmex Corporation: SWOT Analysis
146 Thermo Fisher Scientific: Product Mapping
147 Thermo Fisher Scientific: Overall Financials (2014-2016)
148 Thermo Fisher Scientific: Net Revenue by Business Segment (2014-2016)
149 Thermo Fisher Scientific: Net Revenue by Region (2014-2016)
150 Thermo Fisher Scientific: SWOT Analysis
151 TROVAGENE, INC.: Product Mapping
152 TROVAGENE, INC.: Overall Financials (2014-2016)
153 TROVAGENE, INC.: SWOT Analysis
A biopsy is the most common, definitive medical procedure used for cancer diagnosis and treatment monitoring. Tissue biopsy is the most widely adopted procedure to diagnose cancer. However, a major drawback of the tissue based diagnosis approach is its dependency on invasive surgical procedures which in many instances preclude the regular treatment monitoring and sometimes the initial diagnosis too.
The search for better minimally invasive diagnostic procedures to aid the regular monitoring of the patient’s response towards the treatment, have paved pathway for the most awaited change in diagnostic procedures. In the recent years, the impressive research on cancer biomarkers’ presence in biological fluids, such as blood, which can be collected through minimally invasive techniques has opened up new hopes to develop promising minimally invasive diagnostic procedures. These procedures developed based on the detection of biomarkers in biological fluids which were later named as Liquid biopsy.
Liquid biopsy is a non-invasive medical procedure which has the ability to detect the presence of molecular cancer biomarkers in biological fluids. The derived test results help the doctors in deciding the further steps in the treatment of the cancer patients.
The purpose of the study is to gain a holistic view of the liquid biopsy market in terms of various factors influencing it, such as recent trends, technological advancements, and regulatory aspects of the market. The scope of this report is centered upon conducting a detailed study of the solutions allied with the liquid biopsy market. The global liquid biopsy market has been segmented into five different parts, namely by product, by type of biomarker and technology, by application, by end user, and by geography. These segments have been further segmented into many sub segments to ease the market estimation and to gain a holistic view of the market.
The global liquid biopsy market is anticipated to grow over $4,434 million by 2025. With the growing prominence for non-invasive diagnostic procedures, the global liquid biopsy market is expected to register an impressive double digit growth rate in the forecast period 2016-2025. The global liquid biopsy market, by product, is being dominated by Kits & Consumables, the sub segment was reported to contribute approximately 63% to the global liquid biopsy market value in 2016. The sub segment is expected to maintain its dominating share and is estimated to contribute approximately 61% to the global liquid biopsy market value in 2025.
On the other hand, the global liquid biopsy market, by type of biomarker, is being dominated by Circulating Tumor Cells (CTCs), the sub segment was reported to contribute 56% to the global liquid biopsy market value in 2016. The sub segment is expected to maintain its dominating market share and is estimated to contribute approximately 45% to the global liquid biopsy market value in 2025.
Additionally, the global liquid biopsy market, by application, is being dominated by Oncology Application. The sub segment was estimated to contribute 97% to the global liquid biopsy market value in 2016. The sub segment is expected to maintain its leading share and is estimated to contribute approximately 92% to the global liquid biopsy market value in 2025. The North America liquid biopsy market held the largest market share in 2016. The Asia Pacific liquid biopsy market is expected to register the highest CAGR of 26.3% in the forecast period 2016-2025.
The key players of the market include Adaptive Biotechnologies, ANGLE plc, Biocept Inc., Bio-Rad Laboratories Inc., Cynvenio Biosystems, Inc., Epic Sciences, F. Hoffmann-La Roche AG, Genomic Health, Guardant Health, Inc., Illumina, Inc., Janssen Diagnostics, LLC, MDxHealth, Menarini Silicon Biosystems., Myriad Genetics, Natera, Inc., NeoGenomics Laboratories, Inc., QIAGEN, RainDance Technologies, Inc., Sysmex Inostics GmbH, Thermo Fisher Scientific, and Trovagene Inc.
Currently, a significant work is being carried out to develop medical procedure based on liquid biopsy, for diagnosis of several diseases other than cancer. Through the detection of different biomarkers, the diagnosis of cardiovascular diseases, infections, immunological and genetic disorders is certainly possible and opens new hopes for the patients. The development of test kits to diagnose the above mentioned diseases appears to be a great opportunity to serve the market, for both the new and the existing players.
North America
U.S.
Canada
Europe
U.K.
Germany
France
Rest of Europe
Asia Pacific
China
Japan
India
Row
Global liquid biopsy market, Liquid biopsy market, liquid biopsy market report, Global Liquid Biopsy Market Share, Liquid Biopsy Market Size, Global Liquid Biopsy End User Market
Cancer, a global pandemic is one of the leading cause of deaths worldwide. According to the American Cancer Society, 1 in 8 deaths worldwide is caused by cancer. According to the research study conducted by the International Agency for Research, approximately 14.1 million new cancer cases were detected and 8.2 million devastating cancer deaths were reported in 2012. Moreover, considering the present rates, the number of cases detected are expected to grow over 21.7 million while, the death counts are expected to reach 13 million.
The rise in the count of cancer cases has been significantly increasing economic burden globally and was estimated to be approximately $1.16 trillion in 2010. Several developed countries such as U.S., U.K., Germany, France, and Canada, among others have been making strenuous efforts to develop actionable measures to control the prevalence of cancer. World Health Organization (WHO), aided by aforementioned developed countries has been significantly supporting several developing countries, to combat cancer prevalence.
The lack of medical procedures enabling early detection and continuous monitoring of cancer patient are the key factors aiding the rise in the count of cancer cases worldwide. Development of medical procedures enabling continuous monitoring of cancer patient and personalized treatments would significantly decrease the count of cancer mortalities.
Presently, the tissue biopsy is the most widely adopted procedure to diagnose cancer. However, its dependency on invasive surgical procedures which in many instances often precludes the regular treatment monitoring and the initial diagnosis had initiated the development of better minimal invasive procedures. The impressive research on molecular technologies, cancer biomarkers and biomarkers presence in body fluids, had opened up pathways for development of a significant non-invasive diagnostic procedure namely Liquid Biopsy.
According to the latest report by BIS Research, titled ‘Global Liquid Biopsy Market, Analysis and Forecast (2017 to 2025)', the global liquid biopsy market is expected to grow at a CAGR 22.5% from 2017 to 2025. The features such as non-invasiveness, real-time monitoring, and diagnosis of mutations in different organs with use of just one sample, have gained the liquid biopsy a widespread popularity among physicians.
Few Companies Mentioned in the Report:
• Adaptive Biotechnologies
• ANGLE plc
• Biocept Inc.
• Bio-Rad Laboratories Inc.
• Cynvenio Biosystems, Inc.
• Epic Sciences
• F. Hoffmann-La Roche AG
• Genomic Health
• Guardant Health, Inc.
• Illumina, Inc.
• Janssen Diagnostics, LLC
• MDxHealth
• Menarini Silicon Biosystems.
• Myriad Genetics
• Natera, Inc.
• NeoGenomics Laboratories, Inc.
• QIAGEN
• RainDance Technologies, Inc.
• Sysmex Inostics GmbH
• Thermo Fisher Scientific
• Trovagene Inc.
Key questions addressed in the report:
Adaptive Biotechnologies
ANGLE plc
Biocept, Inc.
Bio-Rad Laboratories, Inc.
CareDx, Inc.
Cynvenio Biosystems, Inc.
Epic Sciences, Inc.
F. Hoffmann-La Roche AG
Genomic Health, Inc.
GUARDANT HEALTH, INC
Illumina, Inc.
JOHNSON & JOHNSON
MDxHealth, Inc.
Myriad Genetics, Inc.